{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:33:01Z","timestamp":1778643181745,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek Vlaanderen","doi-asserted-by":"publisher","award":["1125825N"],"award-info":[{"award-number":["1125825N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004385","name":"Universiteit Gent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003441","name":"Universitair Ziekenhuis Gent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003441","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jid.2025.07.027","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T23:24:16Z","timestamp":1755127456000},"page":"393-404.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Downregulated Aryl Hydrocarbon Receptor Expression Is Linked with Increased IFN-\u03b3 Production and Impaired Immune Checkpoint Upregulation in Vitiligo"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7484-8413","authenticated-orcid":false,"given":"Arno","family":"Belpaire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-634X","authenticated-orcid":false,"given":"Annelies","family":"Demeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9634-5342","authenticated-orcid":false,"given":"Danique","family":"Berrevoet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8815-5485","authenticated-orcid":false,"given":"Filip","family":"Van Nieuwerburgh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-7498","authenticated-orcid":false,"given":"Elise","family":"Van Caelenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Papageorgiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-8195","authenticated-orcid":false,"given":"Nanja","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-3546","authenticated-orcid":false,"given":"Reinhart","family":"Speeckaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.07.027_bib1","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678999","article-title":"IDO1 expression in ovarian cancer induces PD-1 in T cells via aryl hydrocarbon receptor activation","volume":"12","author":"Amobi-McCloud","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.it.2012.05.004","article-title":"Defining the human T helper 17 cell phenotype","volume":"33","author":"Annunziato","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-06231-0","article-title":"B-cell-specific checkpoint molecules that regulate anti-tumour immunity","volume":"619","author":"Bod","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jid.2025.07.027_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2024.1454947","article-title":"Anxiety-depression: a pivotal mental factor for accelerating disease progression and reducing curative effect in vitiligo patients","volume":"15","author":"Cao","year":"2024","journal-title":"Front Psychol"},{"key":"10.1016\/j.jid.2025.07.027_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdermsci.2024.06.003","article-title":"Dysregulated tryptophan metabolism and AhR pathway contributed to CXCL10 upregulation in stable non-segmental vitiligo","volume":"115","author":"Chen","year":"2024","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jid.2025.07.027_bib7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s10120-023-01429-7","article-title":"Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients","volume":"26","author":"Chivu-Economescu","year":"2023","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.jid.2025.07.027_bib8","author":"Dahl"},{"key":"10.1016\/j.jid.2025.07.027_bib9","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/ijms26041618","article-title":"The aryl hydrocarbon receptor (AHR): peacekeeper of the skin","volume":"26","author":"Dawe","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2025.07.027_bib10","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1007\/s00262-023-03543-y","article-title":"An alternatively spliced PD-L1 isoform PD-L1\u03943, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response","volume":"72","author":"Dioken","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jid.2025.07.027_bib11","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.4049\/jimmunol.1700407","article-title":"Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity","volume":"200","author":"Dixon","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2024.113757","article-title":"Comparative analysis of LAG3 antibodies shows differential binding patterns by flow cytometry","volume":"534","author":"Graydon","year":"2024","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jid.2025.07.027_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40425-018-0449-0","article-title":"Soluble immune checkpoints in cancer: production, function and biological significance","volume":"6","author":"Gu","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jid.2025.07.027_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2017.12.012","article-title":"Regulation of the immune response by the aryl hydrocarbon receptor","volume":"48","author":"Guti\u00e9rrez-V\u00e1zquez","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2025.07.027_bib15","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/TP.0b013e3181b47f25","article-title":"Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice","volume":"88","author":"He","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jid.2025.07.027_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40272-025-00689-3","article-title":"Tapinarof cream 1%: pediatric first approval","volume":"27","author":"Hoy","year":"2025","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jid.2025.07.027_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1194180","article-title":"ExoPD-L1: an assistant for tumor progression and potential diagnostic marker","volume":"13","author":"Hu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2025.07.027_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2025.07.027_bib19","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jid.2025.07.027_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.956090","article-title":"The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application","volume":"13","author":"Huo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2025.07.027_bib22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-022-01748-6","article-title":"Tapinarof cream 1%: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jid.2025.07.027_bib23","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.3390\/ijms22189879","article-title":"The kynurenine pathway-new linkage between innate and adaptive immunity in autoimmune endocrinopathies","volume":"22","author":"Krupa","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2025.07.027_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169176","article-title":"Soluble B and T lymphocyte attenuator correlates to disease severity in sepsis and high levels are associated with an increased risk of mortality","volume":"12","author":"Lange","year":"2017","journal-title":"PLoS One"},{"issue":"6 Suppl","key":"10.1016\/j.jid.2025.07.027_bib25","article-title":"A new role for the aryl hydrocarbon receptor (AhR) as a proximal mediator of immune checkpoints (PD-L1\/2 and IDO1) in non-small cell lung cancer: Insights into an interferon-induced, lncRNA- and JAK\/STAT-mediated signaling pathway","volume":"84","author":"Lara","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2025.07.027_bib26","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.emboj.7601520","article-title":"Metalloproteases regulate T-cell proliferation and effector function via LAG-3","volume":"26","author":"Li","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.jid.2025.07.027_bib27","article-title":"The role of aryl hydrocarbon receptor in vitiligo: a review","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdcr.2023.06.051","article-title":"Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001)","volume":"39","author":"Liu","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2025.07.027_bib29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","article-title":"Tumor-repopulating cells induce PD-1 expression in CD8+ T cells by transferring kynurenine and AhR activation","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jid.2025.07.027_bib30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/vaccines3030703","article-title":"The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity","volume":"3","author":"Mbongue","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jid.2025.07.027_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/jdv.13759","article-title":"New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases","volume":"31","author":"M\u00e9ry-Bossard","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.07.027_bib32","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10020-018-0036-3","article-title":"Changes in the process of alternative RNA splicing results in soluble B and T lymphocyte attenuator with biological and clinical implications in critical illness","volume":"24","author":"Monaghan","year":"2018","journal-title":"Mol Med"},{"key":"10.1016\/j.jid.2025.07.027_bib34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jid.2025.07.027_bib35","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3390\/cells10071603","article-title":"Role of kynurenine pathway in oxidative stress during neurodegenerative disorders","volume":"10","author":"Mor","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jid.2025.07.027_bib36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.9758\/cpn.2020.18.4.507","article-title":"Kynurenine pathway of tryptophan metabolism in neuropsychiatric disorders: pathophysiologic and therapeutic considerations","volume":"18","author":"Muneer","year":"2020","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.jid.2025.07.027_bib37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4049\/jimmunol.179.1.247","article-title":"Aryl hydrocarbon receptor activation during influenza virus infection unveils a novel pathway of IFN-gamma production by phagocytic cells","volume":"179","author":"Neff-LaFord","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cellimm.2005.07.007","article-title":"Alternative splice variants of the human PD-1 gene","volume":"235","author":"Nielsen","year":"2005","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2023.115532","article-title":"Tim-3 facilitates immune escape in benzene-induced acute myeloid leukemia mouse model by promoting macrophage M2 polarization","volume":"266","author":"Ning","year":"2023","journal-title":"Ecotoxicol Environ Saf"},{"key":"10.1016\/j.jid.2025.07.027_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.654960","article-title":"Roles of BTLA in immunity and immune disorders","volume":"12","author":"Ning","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1744980","article-title":"ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance","volume":"9","author":"Orme","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jid.2025.07.027_bib42","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jid.2025.07.027_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12852","article-title":"Multiple paradoxical reactions during ixekizumab therapy","volume":"32","author":"Pirro","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2025.07.027_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1552394","article-title":"BTLA agonist attenuates Th17-driven inflammation in a mouse model of steroid-resistant asthma","volume":"16","author":"Quach","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib45","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/exd.13952","article-title":"Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity","volume":"28","author":"Rahimi","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2025.07.027_bib46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.det.2016.11.014","article-title":"Vitiligo pathogenesis and emerging treatments","volume":"35","author":"Rashighi","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jid.2025.07.027_bib47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41380-019-0414-4","article-title":"The kynurenine pathway: a finger in every pie","volume":"25","author":"Savitz","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jid.2025.07.027_bib48","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1096\/fj.11-201897","volume":"26","author":"Schallreuter","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.jid.2025.07.027_bib49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.envres.2005.12.003","article-title":"Dioxins: an overview","volume":"101","author":"Schecter","year":"2006","journal-title":"Environ Res"},{"key":"10.1016\/j.jid.2025.07.027_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature21080","article-title":"Feedback control of AHR signalling regulates intestinal immunity","volume":"542","author":"Schiering","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jid.2025.07.027_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1156493","article-title":"Transcriptomic signatures reveal a shift towards an anti-inflammatory gene expression profile but also the induction of type I and type II interferon signaling networks through aryl hydrocarbon receptor activation in murine macrophages","volume":"14","author":"Schmidt","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib52","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jid.2025.07.027_bib53","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1074\/jbc.RA117.000631","article-title":"Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR)","volume":"293","author":"Seok","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jid.2025.07.027_bib54","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jid.2025.07.027_bib55","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/exd.13069","article-title":"Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo","volume":"26","author":"Speeckaert","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2025.07.027_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.12.007","article-title":"A cellular and molecular view of T helper 17 cell plasticity in autoimmunity","volume":"87","author":"Stadhouders","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jid.2025.07.027_bib57","article-title":"Anti-IL-17A antibody-associated de novo vitiligo: case report and review of literature","volume":"13","author":"Su","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib58","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jid.2025.07.027_bib59","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/jdv.18134","article-title":"Assessing the dynamic changes in vitiligo: reliability and validity of the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS) [published correction appears in J Eur Acad Dermatol Venereol 2024;38:2326]","volume":"36","author":"van Geel","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.07.027_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdermsci.2019.09.001","article-title":"Role of the aryl hydrocarbon receptor signaling pathway in promoting mitochondrial biogenesis against oxidative damage in human melanocytes","volume":"96","author":"Wang","year":"2019","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jid.2025.07.027_bib66","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/gt.2014.54","article-title":"Effects of upregulated indoleamine 2,3-dioxygenase 1 by interferon \u03b3 gene transfer on interferon \u03b3-mediated antitumor activity","volume":"21","author":"Watcharanurak","year":"2014","journal-title":"Gene Ther"},{"key":"10.1016\/j.jid.2025.07.027_bib61","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1073\/pnas.1118467109","article-title":"Inhibition of cytochrome P4501-dependent clearance of the endogenous agonist FICZ as a mechanism for activation of the aryl hydrocarbon receptor","volume":"109","author":"Wincent","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2025.07.027_bib62","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2025.07.027_bib63","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2025.07.027_bib64","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jid.2025.07.027_bib65","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25023401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25023401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:38:40Z","timestamp":1772833120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25023401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0022202X25023401"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.07.027","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Downregulated Aryl Hydrocarbon Receptor Expression Is Linked with Increased IFN-\u03b3 Production and Impaired Immune Checkpoint Upregulation in Vitiligo","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}